PT  - JOURNAL ARTICLE
AU  - DeStefanis, Rebecca A.
AU  - Olson, Autumn M.
AU  - DeZeeuw, Alyssa K.
AU  - Gillette, Amani A.
AU  - Sha, Gioia C.
AU  - Johnson, Katherine A.
AU  - Kratz, Jeremy D.
AU  - Pasch, Cheri A.
AU  - Clipson, Linda
AU  - Skala, Melissa C.
AU  - Deming, Dustin A.
TI  - Impact of baseline culture conditions of mouse-derived cancer organoids when determining therapeutic response and tumor heterogeneity
AID  - 10.1101/2021.10.12.464087
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.10.12.464087
4099  - http://biorxiv.org/content/early/2021/10/14/2021.10.12.464087.short
4100  - http://biorxiv.org/content/early/2021/10/14/2021.10.12.464087.full
AB  - Representative models are needed to screen new therapies for patients with cancer. Cancer organoids are a leap forward as a culture model that faithfully represents the disease. Mouse-derived cancer organoids (MDCOs) are becoming increasingly popular, however there has yet to be a standardized method to assess therapeutic response and identify subpopulation heterogeneity. There are multiple factors unique to organoid culture that could affect how therapeutic response and MDCO heterogeneity are assessed. Here we describe an analysis of nearly 3,500 individual MDCOs where individual organoid morphologic tracking was performed. Change in MDCO diameter was assessed in the presence of control media or targeted therapies. Individual organoid tracking was identified to be more sensitive to treatment response than well-level assessment. The impact of different generations of mice of the same genotype, different regions of the colon, and organoid specific characteristics including baseline size, passage number, plating density, and location within the matrix were examined. Only the starting size of the MDCO altered the subsequent growth. Here we establish organoid culture parameters for individual organoid morphologic tracking to determine therapeutic response and growth/response heterogeneity for translational studies using murine colorectal cancer organoids.Competing Interest StatementDr. Deming has received research support from Bayer and Takeda. He has also been compensated for serving on a scientific advisory board for Bayer. The other authors declare no potential conflict of interest.